<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922814</url>
  </required_header>
  <id_info>
    <org_study_id>Covid-19 ICU</org_study_id>
    <nct_id>NCT04922814</nct_id>
  </id_info>
  <brief_title>Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19</brief_title>
  <official_title>Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many questions about management of COVID-19 are still not answered. So, we recruit this study&#xD;
      aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to&#xD;
      improve morbidity and mortality of ICU covid patients, to participate in understanding of&#xD;
      real hidden pathophysiology of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>48 hours</time_frame>
    <description>ratio of arterial oxygen pressure in millilitre mercury to fraction of inspired oxygen at same time within the arterial blood gas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lung mechanics</measure>
    <time_frame>48 hours</time_frame>
    <description>measurement of peak and plateau pressures in cm H2O, airway resistance in cm H2O. s/mL, static and dynamic compliance in Litre/cm H2O and positive end expiratory pressure in cm H2O from ventilator settings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>48 hours</time_frame>
    <description>Fulfilment of modified SOFA (Sepsis Organ Failure Assessment) score sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of tissue perfusion</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of tissue perfusion by serum lactate in mmol/L and jugular venous oxygen saturation % from a sample withdrawn from CVP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of Alveolar - Arterial Oxygen difference</measure>
    <time_frame>48 hours</time_frame>
    <description>An arterial canula is to be introduced and a quantity of 0.5 ml of blood samples are obtained from radial artery and arterial blood gas analysis are performed after anti-coagulation by heparin. Alveolar-arterial oxygen tension difference:&#xD;
[P(A-a) DO2] = [(Pa-PH2O) × FiO2%-PaCO2-PaO2]&#xD;
[(760-47) × FiO2%-PaCO2-PaO2]&#xD;
[713 × FiO2%-PaCO2-PaO2]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 days survival</measure>
    <time_frame>after 28 days</time_frame>
    <description>28 days survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording risk factors</measure>
    <time_frame>28 days</time_frame>
    <description>Recording risk factors as diabetes, renal failure, immunosuppression, smoking, COPD and obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording complications</measure>
    <time_frame>28 days</time_frame>
    <description>Recording complications as VAP, HAP, neuromuscular weakness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>Sedation Complication</condition>
  <condition>ICU Acquired Weakness</condition>
  <arm_group>
    <arm_group_label>Control group(group A)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only sedation for mechanically ventilated COVID patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Muscle relaxant group(group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>muscle relaxation</intervention_name>
    <description>They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.</description>
    <arm_group_label>Muscle relaxant group(group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe ARDS: PaO2/FiO2 &lt;200, resistant hypoxemia and tachypnoea (RR &gt; 40&#xD;
             breath/minute)&#xD;
&#xD;
          -  Not relieved by high frequency nasal canula or CPAP.&#xD;
&#xD;
          -  Need for invasive mechanical ventilation (uncooperative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient relatives' refusal&#xD;
&#xD;
          -  Not mechanically ventilated.&#xD;
&#xD;
          -  Combination of female, corticosteroids administration and vecuronium muscle relaxant.&#xD;
&#xD;
          -  Neuromuscular diseases (especially demyelinating diseases).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ayman Abdel Khalek Abou Glala, MD</last_name>
    <phone>0102 567 5901</phone>
    <email>Aymanglala24@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Talaat Ahmed Aly, MD</last_name>
    <phone>01062716629</phone>
    <email>Ahmedtalaat_ahmed@yahoo.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020 Apr 16;55(4). pii: 2000607. doi: 10.1183/13993003.00607-2020. Print 2020 Apr.</citation>
    <PMID>32269085</PMID>
  </results_reference>
  <results_reference>
    <citation>Neto AS, Pereira VG, Espósito DC, Damasceno MC, Schultz MJ. Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials. Ann Intensive Care. 2012 Jul 26;2(1):33. doi: 10.1186/2110-5820-2-33.</citation>
    <PMID>22835162</PMID>
  </results_reference>
  <results_reference>
    <citation>Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guérin C, Prat G, Morange S, Roch A; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372.</citation>
    <PMID>20843245</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ayman Abd El-Khalek Mohammed Glala</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

